Cargando…

The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin

Timosaponin A3 (TA3), extracted from the rhizome of Anemarrhena asphodeloides Bunge, has been reported to affect various diseases, such as cancer, Alzheimer’s disease, and allergies. However, the underlying molecular mechanisms and impacts are largely unknown. In the present study, we hypothesized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Hyun Min, Jee, Wona, Park, Do-il, Kim, Kwan-Il, Jung, Ji Hoon, Jang, Hyeung-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569550/
https://www.ncbi.nlm.nih.gov/pubmed/36233202
http://dx.doi.org/10.3390/ijms231911900
_version_ 1784809882012090368
author Ko, Hyun Min
Jee, Wona
Park, Do-il
Kim, Kwan-Il
Jung, Ji Hoon
Jang, Hyeung-Jin
author_facet Ko, Hyun Min
Jee, Wona
Park, Do-il
Kim, Kwan-Il
Jung, Ji Hoon
Jang, Hyeung-Jin
author_sort Ko, Hyun Min
collection PubMed
description Timosaponin A3 (TA3), extracted from the rhizome of Anemarrhena asphodeloides Bunge, has been reported to affect various diseases, such as cancer, Alzheimer’s disease, and allergies. However, the underlying molecular mechanisms and impacts are largely unknown. In the present study, we hypothesized that TA3 induces apoptosis through the inhibition of c-Myc expression via CNOT2 or MID1IP1 in HCT116. An MTT assay and colony formation assay were used to measure cell viability and proliferation. The protein expression of apoptotic markers and oncogenes was measured using immunoblotting and immunofluorescence assays. The interaction between MID1IP1 and c-Myc was confirmed by performing an immunoprecipitation assay. TA3 markedly inhibited colon cancer cell proliferation. Consistently, TA3 regulated the apoptotic proteins pro-PARP and caspase 3. TA3 inhibited the half-life of c-Myc and suppressed its expression in response to serum stimulation. In addition, TA3 enhanced the apoptotic effects of doxorubicin and 5-FU in colon cancer cells. Altogether, our results reveal a mechanism by which TA3 induces apoptosis through inhibiting c-Myc expression via CNOT2 or MID1IP1 in HCT116, which may help in the development of new therapies for colon cancer based on TA3 in the future.
format Online
Article
Text
id pubmed-9569550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95695502022-10-17 The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin Ko, Hyun Min Jee, Wona Park, Do-il Kim, Kwan-Il Jung, Ji Hoon Jang, Hyeung-Jin Int J Mol Sci Article Timosaponin A3 (TA3), extracted from the rhizome of Anemarrhena asphodeloides Bunge, has been reported to affect various diseases, such as cancer, Alzheimer’s disease, and allergies. However, the underlying molecular mechanisms and impacts are largely unknown. In the present study, we hypothesized that TA3 induces apoptosis through the inhibition of c-Myc expression via CNOT2 or MID1IP1 in HCT116. An MTT assay and colony formation assay were used to measure cell viability and proliferation. The protein expression of apoptotic markers and oncogenes was measured using immunoblotting and immunofluorescence assays. The interaction between MID1IP1 and c-Myc was confirmed by performing an immunoprecipitation assay. TA3 markedly inhibited colon cancer cell proliferation. Consistently, TA3 regulated the apoptotic proteins pro-PARP and caspase 3. TA3 inhibited the half-life of c-Myc and suppressed its expression in response to serum stimulation. In addition, TA3 enhanced the apoptotic effects of doxorubicin and 5-FU in colon cancer cells. Altogether, our results reveal a mechanism by which TA3 induces apoptosis through inhibiting c-Myc expression via CNOT2 or MID1IP1 in HCT116, which may help in the development of new therapies for colon cancer based on TA3 in the future. MDPI 2022-10-07 /pmc/articles/PMC9569550/ /pubmed/36233202 http://dx.doi.org/10.3390/ijms231911900 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ko, Hyun Min
Jee, Wona
Park, Do-il
Kim, Kwan-Il
Jung, Ji Hoon
Jang, Hyeung-Jin
The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title_full The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title_fullStr The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title_full_unstemmed The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title_short The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin
title_sort antitumor effect of timosaponin a3 through c-myc inhibition in colorectal cancer cells and combined treatment effect with 5-fu or doxorubicin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569550/
https://www.ncbi.nlm.nih.gov/pubmed/36233202
http://dx.doi.org/10.3390/ijms231911900
work_keys_str_mv AT kohyunmin theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT jeewona theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT parkdoil theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT kimkwanil theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT jungjihoon theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT janghyeungjin theantitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT kohyunmin antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT jeewona antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT parkdoil antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT kimkwanil antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT jungjihoon antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin
AT janghyeungjin antitumoreffectoftimosaponina3throughcmycinhibitionincolorectalcancercellsandcombinedtreatmenteffectwith5fuordoxorubicin